Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 26439225 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 402 | 26439271 |
US |
86 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 403 | 26439289 |
US |
32 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 404 | 26439354 |
US |
57 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 405 | 26439380 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 406 | 26439499 |
US |
2 | |
Accidental exposure to product, Device use error, Exposure via skin contact, Off label use, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 407 | 26439946 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 408 | 26440345 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 409 | 26440660 |
US |
2 | |
Injection site urticaria, Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 410 | 26441158 |
US |
65 | 1 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 411 | 26431036 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 412 | 26431104 |
US |
1 | |
Injection site pain, Headache, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, MONTELUKAST SODIUM, MONTELUKAST, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, |
||||
| 413 | 26431210 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 414 | 26431215 |
US |
81 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, SARILUMAB, |
||||
| 415 | 26431237 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 416 | 26431290 |
US |
9 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 417 | 26431315 |
US |
69 | 1 |
Blood glucose increased, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 418 | 26431363 |
US |
58 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 419 | 26431369 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 420 | 26431396 |
US |
52 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 421 | 26431495 |
US |
25 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 422 | 26431510 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 423 | 26431807 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 424 | 26431816 |
US |
53 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 425 | 26432526 |
US |
26 | 2 |
Exposure via skin contact, Product dose omission issue, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, |
||||
| 426 | 26433056 |
US |
||
Exposure via skin contact, Device breakage, Product container issue, |
||||
ONABOTULINUMTOXINA, |
||||
| 427 | 26433239 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, Device difficult to use, Device mechanical issue, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 428 | 26433846 |
US |
81 | 2 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 429 | 26433868 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 430 | 26433912 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 431 | 26433931 |
US |
52 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 432 | 26433950 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 433 | 26433973 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 434 | 26433980 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 435 | 26433982 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 436 | 26433983 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 437 | 26434009 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 438 | 26434053 |
US |
16 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 439 | 26434068 |
US |
18 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 440 | 26434078 |
US |
84 | 1 |
Injection site pain, Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 441 | 26434106 |
US |
2 | |
Pruritus, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 442 | 26434142 |
US |
12 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 443 | 26434196 |
US |
7 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 444 | 26434200 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 445 | 26434225 |
US |
54 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 446 | 26434231 |
US |
12 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 447 | 26434243 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 448 | 26434273 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 449 | 26434301 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 450 | 26434310 |
US |
68 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 451 | 26434335 |
US |
12 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 452 | 26434356 |
US |
56 | 1 |
Injection site urticaria, Swelling face, Skin discolouration, Pain, Skin warm, Erythema, Arthralgia, Accidental exposure to product, Exposure via skin contact, Urticaria, Product administered at inappropriate site, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, |
||||
| 453 | 26434365 |
US |
62 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 454 | 26434408 |
US |
57 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 455 | 26434434 |
US |
36 | 1 |
Injection site urticaria, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 456 | 26434530 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 457 | 26434844 |
US |
76 | 2 |
Rash pruritic, Skin lesion, Injection site mass, Injection site erythema, Pruritus, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DENOSUMAB, PREGABALIN, AMLODIPINE BESYLATE, DULOXETINE HYDROCHLORIDE, DULOXETINE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, DULOXETINE HYDROCHLORIDE, DULOXETINE, CALCIUM, ERGOCALCIFEROL, VITAMIN E, |
||||
| 458 | 26434915 |
US |
2 | |
Injection site discharge, Exposure via skin contact, Wrong technique in device usage process, Incorrect dose administered, Wrong technique in product usage process, |
||||
GARADACIMAB, |
||||
| 459 | 26435226 |
US |
2 | |
Injection site erythema, Pruritus, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 460 | 26436126 |
US |
15 | 1 |
Fear of injection, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 461 | 26436233 |
US |
80 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 462 | 26436278 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 463 | 26426254 |
US |
62 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 464 | 26427758 |
US |
53 | 2 |
Off label use, Injection site bruising, Accidental exposure to product, Exposure via skin contact, Product administration error, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 465 | 26428146 |
US |
2 | |
Product dose omission issue, Exposure via skin contact, Device malfunction, Haemorrhage, |
||||
TOCILIZUMAB, |
||||
| 466 | 26428526 |
US |
84 | 1 |
Accidental exposure to product, Exposure via skin contact, Device use error, |
||||
EVOLOCUMAB, |
||||
| 467 | 26429233 |
US |
50 | 1 |
Device use error, Accidental exposure to product, Exposure via skin contact, Product communication issue, Incorrect dose administered by device, |
||||
ERENUMAB-AOOE, |
||||
| 468 | 26429805 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 469 | 26430947 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 470 | 26430968 |
US |
29 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 471 | 26430969 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
INSULIN GLARGINE, |
||||
| 472 | 26430985 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 473 | 26430986 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 474 | 26430993 |
US |
54 | 1 |
Injection site pain, Injection site irritation, Muscle twitching, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 475 | 26420542 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 476 | 26420613 |
US |
64 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Underdose, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 477 | 26420753 |
US |
88 | 2 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 478 | 26420872 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 479 | 26421000 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 480 | 26421116 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 481 | 26421405 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 482 | 26421516 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 483 | 26421831 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 484 | 26422096 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ALBUTEROL SULFATE, VITAMIN C, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BIOTIN, CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, FLECAINIDE ACETATE TABLET, FLECAINIDE ACETATE, INSULIN LISPRO, INSULIN GLARGINE, IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE, IRON, LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST SODIUM, MONTELUKAST, SERTRALINE HYDROCHLORIDE, TIRZEPATIDE, ZOLEDRONIC ACID, |
||||
| 485 | 26422182 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 486 | 26422283 |
US |
2 | |
Dyspnoea, Drug dose omission by device, Device defective, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 487 | 26422732 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 488 | 26423376 |
CA |
61 | 1 |
Death, Exposure via skin contact, Accidental exposure to product, Device difficult to use, Device malfunction, Incorrect dose administered, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE SULFATE, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, SULFASALAZINE, METHADONE, |
||||
| 489 | 26423772 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 490 | 26423921 |
US |
27 | 2 |
Exposure via skin contact, Injection site haemorrhage, Injection site erythema, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
BELIMUMAB, |
||||
| 491 | 26424440 |
US |
51 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 492 | 26424557 |
US |
85 | 2 |
Accidental exposure to product, Exposure via skin contact, Exposure via ingestion, |
||||
DUPILUMAB, |
||||
| 493 | 26425303 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, Device delivery system issue, |
||||
SECUKINUMAB, |
||||
| 494 | 26418954 |
US |
68 | 1 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 495 | 26418962 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 496 | 26418965 |
US |
64 | 2 |
Pruritus, Drug dose omission by device, Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 497 | 26418983 |
US |
81 | 1 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Off label use, Device use error, |
||||
MEPOLIZUMAB, |
||||
| 498 | 26419045 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 499 | 26419059 |
US |
69 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE-YFGN, INSULIN GLARGINE, SEMAGLUTIDE, ORAL SEMAGLUTIDE, SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 500 | 26419121 |
US |
70 | 1 |
Subretinal fluid, Dry eye, Eye pruritus, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28